CAR T cell News and Research

RSS

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

So-called CAR-T cell therapy is a promising option for treating around a fifth of patients with diffuse large B-cell lymphoma.

4 Dec 2018

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

A new article published today in The Lancet Oncology shows 39 percent of large B cell lymphoma patients treated with the chimeric antigen receptor T-cell therapy Yescarta remained in remission more than two years following therapy, and more than half of the patients treated remain alive.

4 Dec 2018

New strategies may improve performance of CAR-T cell therapy in treating cancer

Mayo Clinic researchers have developed two new strategies that may improve the performance of chimeric antigen receptor therapy in treating cancer. They are presenting results of their preclinical research at the 2018 annual meeting of the American Society of Hematology in San Diego.

3 Dec 2018

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Chimeric antigen receptor T-cell therapy, or CAR T, was named the 2017 Advance of the Year by the American Society of Clinical Oncology. The FDA approved two CAR T products last year for treatment of adult large B-cell lymphoma based on the exceptional patient outcomes seen in clinical trials.

3 Dec 2018

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

A follow-up analysis of patients enrolled in a Phase I/II multi-center trial for diffuse large B-cell lymphoma reported 51 percent of patients receiving an anti-CD19 chimeric antigen receptor (CAR T) called axi-cel were still alive two years post-treatment.

3 Dec 2018

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

In an update to a global clinical trial stretching from Philadelphia to four continents, the chimeric antigen receptor (CAR) T cell therapy Kymriah (tisagenlecleucel, formerly CTL019) led to long-lasting remissions in patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL).

3 Dec 2018

First-ever European Meeting on CAR T Cell Therapy represents educational opportunity for healthcare professionals

CAR T Cell Therapy is revolutionizing the field of hematologic malignancies and has the potential to achieve cure for a number of dreadful diseases.

29 Nov 2018

New study sheds light on how CAR T cell therapy works

Cancer remains the second-leading cause of death in the United States. This year, an estimated 1.7 million new cases will be diagnosed, with nearly 610,000 people expected to die from the disease, according to the National Cancer Institute.

8 Nov 2018

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute, have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

5 Nov 2018

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

The door to discovery has been opened, and the traditional flow cytometry market is set to see a paradigm shift. With its new Northern Lights series of advanced flow cytometry systems, Cytek Biosciences Inc. is making three lasers and more than 24 colors possible at a price point typically attached to systems with far fewer capabilities.

From Cytek Biosciences 2 Nov 2018

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

City of Hope, a world-renowned independent cancer research and treatment center, and its affiliate, Translational Genomics Research Institute (TGen), have announced a letter of intent to develop a state-of-the-art cell therapy manufacturing facility in the Phoenix Metropolitan Area, a move that would improve the speed at which stem cell research and cancer treatment is delivered.

2 Nov 2018

Study shows how machinery within immune system activates T cells to attack cancer

In just a few years, CAR T-cell and other adoptive T-cell therapies have emerged as among the most promising forms of cancer immunotherapy.

31 Oct 2018

New Penn Medicine Center offers hope in the fight against glioblastoma

Today, Penn Medicine is announcing the newest Translational Center of Excellence in the Abramson Cancer Center, focused on Glioblastoma Multiforme, the most common and lethal form of brain cancer.

30 Oct 2018

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

Women with HER2-positive breast cancer that has spread to the brain need more treatment options, and City of Hope and Mustang Bio Inc. are meeting that challenge.

30 Oct 2018

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

A new program project grant from the National Cancer Institute will fund research by the Translational Center of Excellence for Lung Cancer Immunology at the Abramson Cancer Center of the University of Pennsylvania to improve the effectiveness of chimeric antigen receptor T cell therapy at fighting solid tumors.

23 Oct 2018

Study highlights existence of barriers to early clinical trial access for adolescents and young adults

Young cancer patients at the crossroads of childhood and adulthood seem to be stuck in a treatment impasse. A study to be presented at the ESMO 2018 Congress in Munich, has highlighted the existence of barriers to the inclusion of 12 to 25-year-olds in both adult and pediatric early phase clinical trials, suggesting a need for more tailored approaches to give this patient population better access to therapeutic innovation.

22 Oct 2018

CAR T cell News and Research

CAR-T cell therapy appears to be promising option for treating large B-cell lymphoma

Study: 39% of B cell lymphoma patients treated with CAR T therapy remain in remission

New strategies may improve performance of CAR-T cell therapy in treating cancer

Study shows outcomes of CAR T-cell therapy when used as standard of care for lymphoma

Study: 51% of patients alive two years after receiving CAR-T therapy for diffuse large B-cell lymphoma

CAR T therapy can lead to long-lasting remissions in patients with r/r diffuse large B-cell lymphoma

First-ever European Meeting on CAR T Cell Therapy represents educational opportunity for healthcare professionals

New study sheds light on how CAR T cell therapy works

TGen and City of Hope announce letter of intent to develop new cell therapy manufacturing facility

Cytek Biosciences introduces new Northern Lights series of advanced flow cytometry systems

TGen, City of Hope to develop cell therapy manufacturing facility in Phoenix

Study shows how machinery within immune system activates T cells to attack cancer

New Penn Medicine Center offers hope in the fight against glioblastoma

New City of Hope CAR T cell trial focuses on HER2-positive breast cancer patients with brain metastases

NCI grant awarded to Abramson Cancer Center to study CAR T cells In solid tumors

Study highlights existence of barriers to early clinical trial access for adolescents and young adults

A new promising method for treating pancreatic cancer

New tool can help researchers split and reassemble proteins

Why patients with ALL relapse after CAR-T cell therapy

Why patients with ALL relapse after CAR-T cell therapy

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News